sVE-cadherin and sCD146 serum levels in patients with multiple myeloma

Clinical and Laboratory Haematology

Volumn 28, Issue 1, 2006, Pages 36-39

  Wrobel, T ^a   Mazur, G ^a   Wolowiec, D ^a   Jazwiec, B ^a   Sowinska, E ^a   Kuliczkowski, K ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Angiogenesis; Multiple myeloma; sCD146; sVE cadherin

Indexed keywords

ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; PROTEIN CD146; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS;

AGED; ANTIGENS, CD; ANTIGENS, CD146; CADHERINS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REMISSION INDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 33645051735     PISSN: 01419854     EISSN: 13652257     Source Type: Journal    
DOI: 10.1111/j.1365-2257.2006.00756.x     Document Type: Article

References (18)

1. Bardin N. Anfosso F. Masse J.M. Cramer E. Sabatier F. Le Bivic A. Sampol J. Dignat-George F. 2001 Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion Blood 98 3677 3684
2. Bardin N. Moal V. Anfosso F. Daniel L. Brunet P. Sampol J. Dignat-George F. 2003 Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration Thrombosis and Haemostasis 90 915 920
3. Beerepoot L.V. Mehra N. Vermaat J.S.P. Zonnenberg B.A. Gebbink M. Voest E. 2004 Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients Annals of Oncology 15 139 145
4. Blade J. Samson D. Reece D. Apperley J. Bjorkstrand B. Gahrton G. Gertz M. Giralt S. Jagannath S. Vesole D. 1998 Criteria for definition of response, relapse and progression in multiple myeloma after high-dose therapy British Journal of Haematology 102 1115 1123
5. Di Raimondo F. Azzaro M.P. Palumbo G. Bagnato S. Giustolisi G. Floridia P. Sortino G. Giustolisi R. 2000 Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood Haematologica 85 800 805
6. Folkman J. 2001 Can mosaic tumor vessels facilitate molecular diagnosis of cancer Proceedings of National Academy of Science of the USA 98 398 400
7. Furstenberger G. von Moos R. Senn H.J. Boneberg E.M. 2005 Real-time PCR of CD146 mRNA in peripheral blood enables the relative quantification of circulating endothelial cells and is an indicator of angiogenesis British Journal of Cancer 93 793 798
8. Malyszko J. Malyszko J.S. Brzosko S. Wolczynski S. Mysliwiec M. 2004 Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients Journal of Clinical Endocrinology and Metabolism 89 4620 4627
9. Mancuso P. Burlini A. Pruneri G. Goldhirsh A. Martinelli G. Bertolini F. 2001 Resting and activated endothelial cells are increased in the peripheral blood in cancer patients Blood 97 3658 3661
10. Montestiroli S. Mancuso P. Burlini A. Pruneri G. Dell'Agnola C.H. Gobbi A. Martinelli G. Bertolini F. 2001 Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma Cancer Research 61 4341 4344
11. Rabascio C. Muratori E. Mancuso P. Calleri A. Raia V. Foutz T. Cinieri S. Veronesi G. Pruneri G. Lampertico P. Iavarone M. Martinelli G. Goldhirsh A. Bertolini F. 2004 Assessing tumor angiogenesis. Increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells Cancer Research 64 4373 4377
12. Rajkumar S.V. Leong T. Roche P.C. Fonseca R. Dispenzieri A. Lacy M.Q. Lust J.A. Witzig T.E. Kyle R.A. Gertz M.A. Greipp P.R. 2000 Prognostic value of bone marrow angiogenesis in multiple myeloma Clinical Cancer Research 6 3111 3116
13. Salven P. Orpana A. Teerenhovi L. Joensuu H. 2000 Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients Blood 96 3712 3718
14. Vacca A. Ria R. Semeraro F. Merchionne F. Coluccia M. Boccaarelli A. Scaavelli C. Nico B. Gernone A. Battelli F. Tabilio A. Guidolin D. Petrucci M.T. Ribatti D. Dammacco F. 2003 Endothelial cells in the bone marrow of patients with multiple myeloma Blood 102 3340 3348
15. Vacca A. Ribatti D. Roncali L. Ranieri G. Serio G. Silvestris F. Dammacco F. 1994 Bone marrow angiogenesis and progression in multiple myeloma British Journal of Haematology 87 503 508
16. Verstovsek S. Kantarjian H. Manshouri T. Cortes J. Giles F.J. Rogers A. Albitar M. 2002 Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia Blood 99 2265 2267
17. Wrobel T. Mazur G. Surowiak P. Dziegiel P. Zubkiewicz L. Jelen M. Kuliczkowski K. 2003 Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of multiple myeloma (MM) patients European Journal of Internal Medicine 14 98 100
18. Zhang H. Vakil V. Braunstein M. Smith E.L. Maroney J. Chen L. Dai K. Berenson J.R. Hussain M.M. Klueppelberg U. Norin A.J. Akman H.O. Ozcelik T. Batuman O.A. 2005 Circulating endothelial progenitor cells in multiple myeloma: implications and significance Blood 105 3286 3294